Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.830
+0.020 (0.52%)
Jun 10, 2026, 1:51 PM EDT - Market open
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$994,489
Market Cap
48.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -8 | -33.33% | 16 | 0 |
| Dec 31, 2024 | 24 | 3 | 14.29% | 24 | 0 |
| Dec 31, 2023 | 21 | -2 | -8.70% | 21 | 0 |
| Dec 31, 2022 | 23 | 7 | 43.75% | 22 | 1 |
| Dec 31, 2021 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Veru Inc. | 20 |
| Tevogen Bio Holdings | 18 |
| Edesa Biotech | 17 |
| Dogwood Therapeutics | 8 |
LTRN News
- 8 days ago - Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300 - TheFly
- 8 days ago - Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - Business Wire
- 22 days ago - Lantern receives successful response to Type C meeting from FDA on LP-300 - TheFly
- 22 days ago - Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - Business Wire
- 25 days ago - Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 25 days ago - Lantern Pharma Earnings release: Q1 2026 - Filings
- 25 days ago - Lantern Pharma Quarterly report: Q1 2026 - Filings
- 26 days ago - Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Business Wire